Nimmagadda Sridhar, Penet Marie-France
Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Front Oncol. 2020 Jan 21;9:1537. doi: 10.3389/fonc.2019.01537. eCollection 2019.
Ovarian cancer is a leading cause of death from gynecological malignancies. Although the prognosis is quite favorable if detected at an early stage, the vast majority of cases are diagnosed at an advanced stage, when 5-year survival rates are only 30-40%. Most recurrent ovarian tumors are resistant to traditional therapies underscoring the need for new therapeutic options. Theranostic agents, that combine diagnostic and therapeutic capabilities, are being explored to better detect, diagnose and treat ovarian cancer. To minimize morbidity, improve survival rates, and eventually cure patients, new strategies are needed for early detection and for delivering specifically anticancer therapies to tumor sites. In this review we will discuss various molecular imaging modalities and targets that can be used for imaging, therapeutic and theranostic agent development for improved diagnosis and treatment of ovarian cancer.
卵巢癌是妇科恶性肿瘤致死的主要原因。尽管早期发现时预后相当良好，但绝大多数病例在晚期才被诊断出来，此时5年生存率仅为30% - 40%。大多数复发性卵巢肿瘤对传统疗法耐药，这凸显了对新治疗方案的需求。正在探索兼具诊断和治疗能力的诊疗试剂，以更好地检测、诊断和治疗卵巢癌。为了将发病率降至最低、提高生存率并最终治愈患者，需要新的策略用于早期检测以及将特异性抗癌疗法输送到肿瘤部位。在本综述中，我们将讨论各种分子成像模式和靶点，这些可用于成像、治疗以及诊疗试剂开发，以改善卵巢癌的诊断和治疗。
